DE60314541D1 - Mindestens zwei ati promotoren enthaltendes rekombinantes pockenvirus - Google Patents

Mindestens zwei ati promotoren enthaltendes rekombinantes pockenvirus

Info

Publication number
DE60314541D1
DE60314541D1 DE60314541T DE60314541T DE60314541D1 DE 60314541 D1 DE60314541 D1 DE 60314541D1 DE 60314541 T DE60314541 T DE 60314541T DE 60314541 T DE60314541 T DE 60314541T DE 60314541 D1 DE60314541 D1 DE 60314541D1
Authority
DE
Germany
Prior art keywords
seq
pox virus
containing recombinant
ati
promoters containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60314541T
Other languages
English (en)
Other versions
DE60314541T2 (de
Inventor
Sonja Leyrer
Paul Howley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bavarian Nordic AS
Original Assignee
Bavarian Nordic AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic AS filed Critical Bavarian Nordic AS
Publication of DE60314541D1 publication Critical patent/DE60314541D1/de
Application granted granted Critical
Publication of DE60314541T2 publication Critical patent/DE60314541T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60314541T 2002-11-25 2003-11-12 Mindestens zwei ati promotoren enthaltendes rekombinantes pockenvirus Expired - Lifetime DE60314541T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200201814 2002-11-25
DK200201814 2002-11-25
PCT/EP2003/012610 WO2004048582A2 (en) 2002-11-25 2003-11-12 Recombinant poxvirus comprising at least two cowpox ati promoters

Publications (2)

Publication Number Publication Date
DE60314541D1 true DE60314541D1 (de) 2007-08-02
DE60314541T2 DE60314541T2 (de) 2008-02-28

Family

ID=32337938

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60314541T Expired - Lifetime DE60314541T2 (de) 2002-11-25 2003-11-12 Mindestens zwei ati promotoren enthaltendes rekombinantes pockenvirus

Country Status (21)

Country Link
US (1) US7300658B2 (de)
EP (1) EP1567653B1 (de)
JP (1) JP2006515170A (de)
KR (1) KR20050083839A (de)
CN (1) CN1717488A (de)
AT (1) ATE365220T1 (de)
AU (1) AU2003293675B2 (de)
CA (1) CA2501168A1 (de)
CY (1) CY1106883T1 (de)
DE (1) DE60314541T2 (de)
DK (1) DK1567653T3 (de)
EA (1) EA012723B1 (de)
ES (1) ES2288634T3 (de)
IL (1) IL167844A (de)
MX (1) MXPA05005549A (de)
NO (1) NO20053125L (de)
NZ (1) NZ540156A (de)
PL (1) PL375740A1 (de)
PT (1) PT1567653E (de)
UA (1) UA85379C2 (de)
WO (1) WO2004048582A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002042480A2 (en) * 2000-11-23 2002-05-30 Bavarian Nordic A/S Modified vaccinia ankara virus variant
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
DK1407033T3 (da) * 2002-05-16 2006-05-22 Bavarian Nordic As Intergeniske områder som insertionssteder i genomet af Modified Vaccinia Virus Ankara (MVA)
US20090098529A1 (en) * 2006-10-16 2009-04-16 Nanhai Chen Methods for attenuating virus strains for diagnostic and therapeutic uses
US20110052627A1 (en) * 2008-06-20 2011-03-03 Paul Chaplin Recombinant modified vaccinia virus measles vaccine
NZ591662A (en) 2008-11-21 2012-10-26 Bavarian Nordic As Vector comprising multiple homologous nucleotide sequences
US8394385B2 (en) * 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
US9567331B2 (en) 2011-11-15 2017-02-14 Trustees Of Boston University Pyridopyrimidinone inhibitors of viruses
US11701418B2 (en) * 2015-01-12 2023-07-18 Geovax, Inc. Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40)
KR20160140075A (ko) 2015-05-29 2016-12-07 코오롱생명과학 주식회사 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
AU2016360763B2 (en) * 2015-11-24 2020-11-05 Glaxosmithkline Intellectual Property Development Limited Stable cell lines for retroviral production
WO2017089307A1 (en) * 2015-11-24 2017-06-01 Glaxosmithkline Intellectual Property Development Limited Transient transfection method for retroviral production
JP7150611B2 (ja) 2016-01-08 2022-10-11 ジオバックス・インコーポレイテッド 腫瘍関連抗原に対する免疫応答を誘起するための組成物及び方法
BR112018015696A2 (pt) 2016-02-03 2018-12-26 Geovax Inc composições e métodos para gerar uma resposta imune para um flavivírus
RU2021128158A (ru) * 2016-08-09 2022-04-07 Сити Оф Хоуп Композиции химерного поксвируса и их применение
US11311612B2 (en) 2017-09-19 2022-04-26 Geovax, Inc. Compositions and methods for generating an immune response to treat or prevent malaria

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443964A (en) * 1987-08-10 1995-08-22 Duke University Poxvirus insertion/expression vector
US5759841A (en) * 1990-11-20 1998-06-02 Virogenetics Corporation Immunological composition of measles virus utilizing recombinant poxvirus
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
MY150893A (en) * 1996-09-24 2014-03-14 Bavarian Nordic As Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
ATE412762T1 (de) * 1999-05-28 2008-11-15 Helmholtz Zentrum Muenchen Vektor zur integration von heterologen sequenzen in poxvirusgenomen
MXPA03001680A (es) * 2000-08-29 2004-11-01 Wyeth Corp Empaque de particulas de un replicon del virus de acido ribonucleico (arn) de hebra positiva.

Also Published As

Publication number Publication date
IL167844A (en) 2011-03-31
AU2003293675A1 (en) 2004-06-18
ES2288634T3 (es) 2008-01-16
AU2003293675B2 (en) 2009-04-23
CY1106883T1 (el) 2012-09-26
MXPA05005549A (es) 2005-08-16
WO2004048582A2 (en) 2004-06-10
UA85379C2 (ru) 2009-01-26
WO2004048582A3 (en) 2004-08-12
NZ540156A (en) 2006-11-30
EP1567653B1 (de) 2007-06-20
NO20053125D0 (no) 2005-06-24
ATE365220T1 (de) 2007-07-15
US20060153874A1 (en) 2006-07-13
CA2501168A1 (en) 2004-06-10
NO20053125L (no) 2005-06-24
EA012723B1 (ru) 2009-12-30
DE60314541T2 (de) 2008-02-28
DK1567653T3 (da) 2007-10-15
EP1567653A2 (de) 2005-08-31
PL375740A1 (en) 2005-12-12
EA200500879A1 (ru) 2005-10-27
CN1717488A (zh) 2006-01-04
KR20050083839A (ko) 2005-08-26
PT1567653E (pt) 2007-10-01
JP2006515170A (ja) 2006-05-25
US7300658B2 (en) 2007-11-27

Similar Documents

Publication Publication Date Title
NO20053125D0 (no) Rekombinant koppevirus omfattende i det minste to kukoppe-ati-promotere.
JP6291467B2 (ja) 組換えウイルス発現のためのプロモーター
HK1076835A1 (en) Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
RU98101904A (ru) Рекомбинантный вирус mva и его использование
WO2000003030A3 (en) Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
UA82998C2 (ru) Экспрессия генов в модифицированном вирусе коровьей оспы ankara с использованием коровьего поксвирусного промотора аті
US6869793B2 (en) Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
IL204539A (en) Foxvirus virus containing defective genes and a losing gene
JP2001081042A5 (de)
WO2001089559A3 (en) Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine
CN101142319B (zh) 基于使用修饰安卡拉痘苗病毒的疫苗
DK1425404T3 (da) Vaccinia-MVA-E3L-mutanter og anvendelse deraf
WO2003040305A3 (en) Porcine adenovirus e1 and e4 regions
CA2372709A1 (en) Vector for integration of heterologous sequences into poxviral genomes
HK1055762A1 (en) Generation of human cytomegalovirus yeast artificial chromosome recombinants
AU2003255315A1 (en) Vaccinia virus host range genes to increase the titer of avipoxviruses
JPWO2021154828A5 (de)
NZ512341A (en) Polynucleotides between 15 and 100 base pairs in length coding for parapoxvirus ovis (PPVO)/vaccinia virus recombinant (VVOV) viral genome fragments
JP2009232836A5 (de)
NZ507942A (en) Viral chimeras comprised of CAEV and HIV-1 genetic elements
RU2023132190A (ru) Новые последовательности белков и нуклеиновых кислот для вакцин против covid-19
Cheng et al. 106 Gln Glu Glu 122 Met Met Val
DK200201813A (da) Ekspression af gener i modificeret vaccinia virus ankara ved brug af ATI promotoren fra ko-kopper
BR0316553A (pt) Poxvìrus recombinante que compreende pelo menos dois promotores ati de varìola bovina

Legal Events

Date Code Title Description
8364 No opposition during term of opposition